K. Kono, I. Tatara, S. Takeda
Jun 1, 1996
Citations
0
Influential Citations
2
Citations
Quality indicators
Journal
Current Therapeutic Research-clinical and Experimental
Abstract
Abstract The complement inhibitor nafamostat mesylate (6-amidino-2-naphthyl-4-guanidinobenzoate dimethane sulfonate) was used to treat an 18-year-old woman with systemic lupus erythematosus and nephrotic syndrome who was resistant to treatment with prednisolone, dipyridamole, and mizoribine. Nafamostat mesylate was effective in treating the patient's proteinuria and hypocomplementemia, but long-term treatment was not possible because of allergic reactions